lomibuvir
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2009 (NCT00911963)
Timeline
Indications
Mechanism of action
- Hepatitis C virusINHIBITOR
Hepatitis C virus inhibitor
- RNA-directed RNA polymeraseNEGATIVE ALLOSTERIC MODULATOR
RNA-directed RNA polymerase negative allosteric modulator
Thumb II site
- Hepatitis C virus NS5B RNA-dependent RNA polymeraseNEGATIVE ALLOSTERIC MODULATOR
Hepatitis C virus NS5B RNA-dependent RNA polymerase negative allosteric modulator
Thumb II site
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C)C#Cc1cc(N(C(=O)[C@H]2CC[C@H](C)CC2)[C@H]2CC[C@H](O)CC2)c(C(=O)O)s1- Mol. weight
- 445.63 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3039503 ↗
Also known as
- lomibuvir
- lomibuvir
- lomibuvir
- lomibuvir
- vch-222
- vch-222
- vx-222
- vx-222
- vx-222
- vx-222
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01581138 | Phase 2 | Jul 1, 2012 | Vertex |
| NCT01516918 | Phase 2 | Feb 1, 2012 | Vertex |
| NCT01080222 | Phase 2 | Aug 1, 2010 | Vertex |
| NCT00958152 | Phase 1 | Aug 1, 2009 | Vertex |
| NCT00911963 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2009 | Vertex, ViroChem Pharma |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vertex | For profit | 5 | 5 | 2 | 2009 |
| ViroChem Pharma | For profit | 1 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1